Published:10/06/2021

Vectura Group plc, an industry-leading specialist inhalation CDMO, today announces the successful completion of a management buy-out of its oral manufacturing subsidiary in Lyon, Skyepharma Production SAS.

In 2019, Vectura Group made the strategic decision to become a fully focussed inhalation CDMO and work with more customers and partners in this space.

After carrying out a strategic review of core activities and site footprint, the Group decided to rationalise its overall site network and prioritise the development of capabilities in the inhalation space.

Click here for the full update.

Attachments

  • Original document
  • Permalink

Disclaimer

Vectura Group plc published this content on 10 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 June 2021 06:43:00 UTC.